Get started
Work

Supplementary Figure 3 from HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

Year: 2023
Type: supplementary-materials
Abstract: PDX tumor growth of patient 2,4,5 under the treatment of indicated drug
DOI: 10.1158/1078-0432.22464680.v1
Authors: Dongsheng Wang, Guoqing Qian, Hongzheng Zhang, Kelly R. Magliocca, Sreenivas Nannapaneni, A.R.M. Ruhul Amin, Michael Rossi, Mihir Patel, Mark El-Deiry, J. Trad Wadsworth, Zhengjia Chen, Fadlo R. Khuri, Dong M. Shin, Nabil F. Saba, Zhuo G. Chen
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4361925039
Cites:
Cited by:
Related to: 10